Polyrizon
PLRZ | NASDAQ
$10.70
-$0.35 (-3.17%)
At close: Nov 16, 2026, 4:00 PM ET
$11.15
+$0.45 (+4.21%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Polyrizon Company Profile
Company profile explainedCompany Profile
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
Key Executives
| Name | Position |
|---|---|
| Tomer Izraeli | Founder, Chief Executive Officer & Director |
| Nir Ben Yosef | Chief Financial Officer & Compliance Officer |
| Tidhar Turgeman | Chief Technology Officer |
| Eyal S. Ron | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | 6-K | Filing |
| Oct 07, 2026 | S-8 | Filing |
| Oct 05, 2026 | 6-K | Filing |
| Oct 01, 2026 | EFFECT | Filing |
| Sep 28, 2026 | F-1/A | [Amend] Filing |
| Sep 28, 2026 | 6-K | Filing |
| Sep 18, 2026 | F-1 | Filing |
| Sep 10, 2026 | D | Filing |
| Sep 04, 2026 | 6-K | Filing |
| Sep 04, 2026 | 6-K | Filing |
Polyrizon
| Country | Israel |
| IPO Date | Oct 29, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Tomer Izraeli |
Contact Details
5 Ha-Tidhar Street Ra'anana,
TA 4321545 Israel
Stock Details
| Ticker Symbol | PLRZ |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001893645 |
| CUSIP Number | M79549206 |
| ISIN Number | IL0011814113 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove PLRZ